ASEAN e-commerce logistics market was valued at $4.8 billion in 2025 and is projected to reach $17.1 billion by 2035, growing at a CAGR of 13.4% during the forecast period (2026–2035). The rapid acceleration of mobile-led e-commerce adoption across ASEAN economies, particularly in Indonesia, Vietnam, Thailand, and the Philippines, is directly strengthening demand in the ASEAN e-commerce logistics market by driving higher order volumes and delivery frequency. Rising smartphone penetration and expanding access to digital payment platforms have supported sustained growth in daily active users on shopping and marketplace applications across the region.

European osteoarthritis therapeutics market was valued at $3,304.0 million in 2025 and is projected to reach $7,052.1 million by 2035, growing at a CAGR of 8.2% during the forecast period (2026–2035). Increased regulatory approvals of osteoarthritis therapies by European manufacturers are a key driver for growth in the market, as locally developed drugs expand treatment availability and reinforce clinician confidence in therapeutic intervention. European pharmaceutical firms are actively advancing product portfolios through new molecule approvals and expanded indications, with regulatory oversight by the European Medicines Agency (EMA) ensuring safety and efficacy across member states.

European High-Performance Liquid Chromatography (HPLC) market was valued at $1,696.8 million in 2025 and is projected to reach $2462.1 million by 2035, growing at a CAGR of 4.2% during the forecast period (2026-2035). Expanding pharmaceutical manufacturing and stringent quality control requirements in Europe are key drivers for this market in the region. The European Medicines Agency (EMA) and national competent authorities enforce rigorous Good Manufacturing Practice (GMP) standards to ensure that pharmaceutical products consistently meet predefined quality, safety, and efficacy criteria before they reach patients.

BRICS e-commerce logistics market was valued at $183.3 billion in 2025 and is projected to reach $525.2 billion by 2035, growing at a CAGR of 12.4% during the forecast period (2026–2035). The rapid acceleration of mobile-led e-commerce adoption across BRICS markets, particularly India, is directly strengthening demand in the BRICS e-commerce logistics market by driving higher order volumes and delivery frequency. Analysis by Affle’s MAAS platform and Sensor Tower indicates sustained growth in daily active users on shopping apps in India, with the top 10 platforms averaging over 7 million daily active users each in Q2 2021, reflecting an 18% year-on-year increase. This expansion in user engagement translates into a consistent rise in transaction volumes, requiring scalable logistics capabilities across last-mile delivery, warehousing, and order fulfillment.

European healthcare contract development and manufacturing organization (CDMO) market was valued at $45.6 billion in 2025 and is growing at a CAGR of 4.9% during the forecast period (2026-2035). The European healthcare contract development and manufacturing organization (CDMO) market is experiencing steady growth as pharmaceutical and biotechnology companies increasingly rely on specialized partners to streamline development and manufacturing processes. Rising demand for biologics, advanced therapies, and complex small-molecule drugs is driving outsourcing to CDMOs with strong regulatory expertise and scalable capabilities. Companies are focusing on integrated service models that cover development, analytical testing, and commercial manufacturing to reduce time-to-market and ensure compliance with stringent European regulations. Technological adoption, including automation, digital quality systems, and advanced process monitoring, is improving efficiency and consistency across production stages. Regional CDMOs are also investing in capacity expansion and facility modernization to accommodate diverse therapeutic portfolios. Collectively, these trends indicate a market shaped by innovation, operational resilience, and increasing strategic partnerships.

Asia-Pacific Osteoarthritis Therapeutics market was valued at $2,744.0 million in 2025 and is projected to reach $6,285.0 million by 2035, growing at a CAGR of 8.2% during the forecast period (2026–2035). Expansion of local pharmaceutical manufacturing capacity in key Asia-Pacific markets such as China and India is strengthening drug availability, lowering treatment costs, and directly supporting growth in the osteoarthritis therapeutics market. According to the Ministry of Commerce and Industry, India’s pharmaceuticals industry reached approximately $57 billion in annual turnover in 2023.

Asia-Pacific High-Performance Liquid Chromatography (HPLC) market was valued at $1,471.3 million in 2025 and is projected to reach $2,357.6 million by 2035, growing at a CAGR of 4.2% during the forecast period (2026-2035). The market is witnessing significant technological advancements that are expanding analytical capabilities and improving laboratory efficiency. Manufacturers are introducing ultra-high-pressure liquid chromatography (UHPLC) systems that deliver faster separations with higher resolution and lower solvent use compared with traditional HPLC platforms. Recent launches include next-generation detectors such as multi-wavelength UV, charged aerosol detectors, and interfaces compatible with mass spectrometry, enabling broader analyte detection and improved quantitative accuracy in complex sample matrices.

US HPLC market was valued at $1,848.4 million in 2025 and is expected to reach $2,763.9 million by 2035, registering a CAGR of 4.2% over the forecast period from 2026 to 2035. The rapid expansion of biologics and complex therapeutic development in the US is a key driver of HPLC demand, particularly for advanced analytical characterization and quality control applications. In 2024, the US Food and Drug Administration approved 50 new therapies, including small molecules and biologics, marking one of the highest annual totals of novel drug approvals on record. 

North America Osteoarthritis Therapeutics market was valued at $4,256.0 million in 2025 and is projected to reach $9,551.3 million by 2035, growing at a CAGR of 8.2% during the forecast period (2026–2035). The availability and widespread clinical adoption of established pharmacologic therapies form a core demand driver for the North American osteoarthritis therapeutics market. NSAIDs, corticosteroids, and opioid analgesics remain integral to osteoarthritis treatment algorithms across early, moderate, and advanced disease stages. Their long-standing regulatory approval and inclusion in clinical guidelines support consistent prescribing across primary care, orthopedics, and pain management settings. As osteoarthritis is a chronic and progressive condition, patients often require sustained pharmacologic intervention over extended periods, reinforcing recurring demand. 

Asia-Pacific healthcare contract development and manufacturing organization (CDMO) market was valued at $170.5 billion in 2025 and is growing at a CAGR of 7.0% during the forecast period (2026-2035). The Asia-Pacific healthcare contract development and manufacturing organization (CDMO) market is gaining prominence as pharmaceutical and biotechnology companies increasingly leverage the region’s manufacturing capabilities and technical expertise. A combination of expanding healthcare demand, cost-efficient operations, and improving regulatory maturity is encouraging sponsors to partner with CDMOs across development and commercial manufacturing stages. Countries in the region are strengthening compliance frameworks and investing in modern facilities, which is enhancing confidence among global clients. The market is also benefiting from a growing pipeline of both innovative and established therapies requiring scalable outsourcing solutions. As a result, the Asia-Pacific is becoming an integral part of global pharmaceutical supply chains. This shift reflects the region’s transition from volume-driven manufacturing to value-added services.